Product Information
Composition:
Lukast LC Kids: Each dispersible tablet contains:
Levocetirizine dihydrochloride 2.5 mg and Montelukast sodium 4.16 mg (equivalent to montelukast 4 mg).
Lukast LC Bilayer tablets: Each bilayered tablet contains:
Levocetirizine dihydrochloride 5 mg and Montelukast sodium 10.4 mg (equivalent to montelukast 10 mg).
Mechanism of action:
- Levocetirizine dihydrochloride
Levocetirizine, the (R) enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1 receptors.
- Montelukast sodium:
Montelukast Sodium is a selective and orally active leukotriene receptor antagonist that inhibits the Cysteinyl leukatrine (CysL.T1) receptor.
Mechanism of action:
The Cysteinyl leukotrines (LTC4, LTD4, and LTE4) are products of arachidonic acid metabolism and released from various cells, including mast cells and eosinophils. CysL.Ts have been correlated with the pathophysiology of asthma and allergic rhinitis. Montelukast binds with high affinity and selectivity to the CysL.T1 receptor in preference to other pharmacologically important airway receptors. Montelukast inhibits physiologic actions of LTD4 at the CysL.T1 receptor without any agonist activity.
Dosage and Administration
Adults (>15 years): 1 tablet once daily.
Packaging
Lukast LC Kids: Pack of 30 dispersible tablets.
Lukast LC Bilayer tablets: Pack of 30 bilayer tablets.
